Compare LPX & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPX | MMED |
|---|---|---|
| Founded | 1973 | 1983 |
| Country | United States | United States |
| Employees | N/A | 2800 |
| Industry | Forest Products | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.5B |
| IPO Year | 1994 | 2026 |
| Metric | LPX | MMED |
|---|---|---|
| Price | $74.21 | $19.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $105.29 | $22.56 |
| AVG Volume (30 Days) | ★ 1.2M | 1.2M |
| Earning Date | 05-06-2026 | 06-03-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $2,708,000,000.00 | N/A |
| Revenue This Year | N/A | $15.99 |
| Revenue Next Year | $11.23 | $10.00 |
| P/E Ratio | $103.30 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $66.12 | $10.65 |
| 52 Week High | $102.86 | $19.76 |
| Indicator | LPX | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 69.59 |
| Support Level | $73.90 | $10.68 |
| Resistance Level | $77.41 | N/A |
| Average True Range (ATR) | 3.26 | 0.80 |
| MACD | 0.36 | 0.10 |
| Stochastic Oscillator | 44.75 | 87.26 |
Louisiana-Pacific Corp is an oriented strand board producer and also offers engineered wood siding used in home construction and repair and remodel projects. The Siding business of the company serves different markets with a broad product portfolio of engineered wood siding, trim, soffit, and fascia. The Company operates through three operating segments: Siding, OSB, and LP South America (LPSA). The company generates majority of its revenue from siding segment.
Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.